Combination Oral Health Care Products Lack Sufficient Safety Data – J&J
This article was originally published in The Rose Sheet
Executive Summary
Johnson & Johnson argues against including combination oral health care products in the OTC antingingivitis/antiplaque monograph in Nov. 25 comments to FDA
You may also be interested in...
Combination Oral Health Care Product Safety Defended By Industry
Combination oral health care products should be permitted in the antigingivitis/antiplaque final monograph, according to the Joint Oral Care Task Group of the Consumer Healthcare Products Association and the Cosmetic, Toiletry and Fragrance Association
Antigingivitis/Antiplaque Combination With Other Actives Excluded In ANPR
FDA's advance notice of proposed rulemaking on OTC antigingivitis/antiplaque products excludes the combination of antigingivitis/antiplaque ingredients with other oral health care ingredients. The 1notice was published in the May 29 Federal Register
FreshBurst Listerine Study Must Exhibit 20% Gingivitis Reduction – FDA
A six-month study of FreshBurst Listerine with Fluoride will need to show "a 20% reduction in gingivitis" over a control to merit agency sign-off, FDA told Pfizer execs at an OTC "feedback" meeting Aug. 27